Bristol-Myers Squibb Company (BMY) Moves Higher Ahead of ASCO Presscast / Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
May 16, 2013 1:16 PM EDT(Updated - May 16, 2013 1:55 PM EDT)
Leerink Swann upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Market Perform to Outperform. The upgrade follows an evaluation of information in the ASCO news release published yesterday.
"Specifically, 5 additional deep responses (>80% tumor shrinkage) were reported at the press... More
Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
May 16, 2013 7:57 AM EDTGoldman Sachs today maintained a Conviction Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY) and raised its price target to $48.00 (from $44.00). The increased price target follows abstract data on nivolumab (PD-1).
"Today's abstracts increase our conviction in BMY's nivolumab (PD-1)... More
